Use of inhibitors of the activity or function of PI3K

Patent metadata

Field	Value
Publication number	US-9949979-B2
Application number	US-201214365512-A
Country	US
Kind code	B2
Filing date	Dec 14, 2012
Priority date	Dec 15, 2011
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

First claim

The invention claimed is:

1. A method of treating a host-mediated immunopathology caused by acute or cerebral malaria in a subject suffering from acute or cerebral malaria, the method comprising the step of administering to the subject a PI3K inhibitor, wherein said PI3K inhibitor has an inhibitory action on the host PI3K isoform delta, wherein inhibition of host PI3K isoform delta causes a reduction of the host immune response to the acute or cerebral malaria, and wherein the PI3K inhibitor is a compound of formula (I) or a tautomer and/or N-oxide and/or pharmaceutically acceptable salt or solvate thereof:

wherein
Y is selected from O and NR 3 ;
R 1 is —C(O)—R 4 ;
R 4 is selected from C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, C 1 -C 8 -alkyl-sulfonyl-C 1 -C 8 -alkyl, heterocyclyl, heterocyclyl-oxy, heterocyclyl-C 1 -C 8 -alkyl, C 3 -C 12 -cycloalkyl, C 3 -C 12 -cycloalkyl-C 1 -C 8 -alkyl, heteroaryl, heteroaryl-oxy, heteroaryl-C 1 -C 8 -alkyl, hydroxy, C 1 -C 8 -alkoxy, amino, N—C 1 -C 8 -alkyl-amino, and N,N-di-C 1 -C 8 -alkyl-amino,
wherein ‘C 1 -C 8 -alkyl’ in N—C 1 -C 8 -alkyl-amino and N,N-di-C 1 -C 8 -alkyl-amino may be unsubstituted or substituted by halogen, hydroxyl, or C 1 -C 4 -alkoxy;
wherein ‘C 3 -C 12 -cycloalkyl’ in C 3 -C 12 -cycloalkyl and C 3 -C 12 -cycloalkyl-C 1 -C 8 -alkyl may be unsubstituted or substituted by 1-5 substituents independently selected from oxo, halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl, and C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl;
wherein ‘heterocyclyl’ is selected from oxiranyl, aziridinyl, oxetanyl, thiethanyl, acetitinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, 2,3-dihydrothiophenyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, thiepanyl, and oxepanyl; each of which is unsubstituted or substituted by 1-5 substituents independently selected from oxo, halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl, and C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl;
wherein ‘heterocyclyl’ can be attached at a heteroatom or a carbon atom and wherein the N and/or S heteroatoms can also optionally be oxidized to various oxidation states; and
wherein ‘heteroaryl’ is selected from furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl,1,3,4-oxadiazolyl, 1,2,5-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, and 1,3,5-triazinyl; each of which is unsubstituted or substituted by 1-5 substituents independently selected from halogen, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl, and C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl; wherein ‘heteroaryl’ can be attached at a heteroatom or a carbon atom and wherein the N and/or S heteroatoms can also optionally be oxidized to various oxidation states;
R 2 is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinoliny, and isoquinolinyl, each of which is unsubstituted or substituted by 1-5 substituents independently selected from halogen, cyano, nitro, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl, and C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl;
R 3 is selected from H, C 1 -C 4 -alkyl, and halo-C 1 -C 4 -alkyl; and
m is selected from 0 and 1.

2. The method of claim 1 , wherein the PI3K inhibitor is a compound of formula (Id′)

and/or tautomers and/or N-oxides and/or pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the PI3K inhibitor is a compound of formula (Ie′)

and/or tautomers and/or N-oxides and/or pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the PI3K inhibitor is a compound in which
R 2 is selected from naphthyl, pyridyl, and pyrimidinyl; each of which is unsubstituted or substituted by 1-3 substituents independently selected from halogen, cyano, nitro, C 1 -C 8 -alkyl, halo-C 1 -C 8 -alkyl, hydroxy-C 1 -C 8 -alkyl, hydroxyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, amino, N—C 1 -C 8 -alkyl-amino, N,N-di-C 1 -C 8 -alkyl-amino, C 1 -C 8 -alkyl-carbonyl, halo-C 1 -C 8 -alkyl-carbonyl, hydroxy-C 1 -C 8 -alkyl-carbonyl, and C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl-carbonyl.

5. The method of claim 1 , wherein the PI3K inhibitor is a compound in which
R 1 is —C(O)—R 4 , and
R 4 is selected from heterocyclyl, C 4 -C 8 -cycloalkyl or heteroaryl;
wherein ‘C 3 -C 12 -cycloalkyl’ may be unsubstituted or substituted by 1-3 substituents independently selected from fluoro, C 1 -C 4 -alkyl, hydroxyl, and C 1 -C 4 -alkoxy;
wherein ‘heterocyclyl’ is selected from pyrrolidinyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, morpholinyl, and piperazinyl; each of which is unsubstituted or substituted by 1-3substituents independently selected from oxo, halogen, C 1 -C 4 -alkyl, hydroxyl, and C 1 -C 4 -alkyl-carbonyl;
wherein ‘heterocyclyl’ can be attached at a heteroatom or a carbon atom and wherein the N and/or S heteroatoms can also optionally be oxidized to various oxidation states;
wherein ‘heteroaryl’ is selected from furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, 1,3,4-oxadiazolyl, pyridyl, and pyrazinyl; each of which is unsubstituted or substituted by 1-3 substituents independently selected from C 1 -C 4 -alkyl,and hydroxyl; and
wherein ‘heteroaryl’ can be attached at a heteroatom or a carbon atom and wherein the N and/or S heteroatoms can also optionally be oxidized to various oxidation states.

6. The method of claim 1 , wherein the PI3K inhibitor is a compound in which
R 1 is —C(O)—R 4 , and
R 4 is selected from C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy-C 1 -C 8 -alkyl, C 1 -C 8 -alkoxy, and N,N-di-C 1 -C 8 -alkyl-amino, wherein ‘C 1 -C 8 -alkyl’ in N,N-di-C 1 -C 8 -alkyl-amino may be unsubstituted or substituted by halogen, hydroxyl, or C 1 -C 4 -alkoxy.

7. The method of claim 1 , wherein the PI3K inhibitor is selected from the group consisting of
{(S)-3-[6-(6-Methoxy-5-methyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone;
{3-[6-(6-Methoxy-5-methyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone;
(S)-1-(3-(6-(6-Methoxy-5-(trifluoromethyl

Assignees

• Novartis Ag

Inventors

• Cooke Nigel Graham
• Fernandes Gomes Dos Santos Paulo Antonio
• Furet Pascal
• Hebach Christina
• Hoegenauer Klemens
• HOLLINGWORTH Gregory
• Kalis Christoph
• Lewis Ian
• Smith Alexander Baxter
• Soldermann Nicolas
• Stauffer Frederic
• Strang Ross
• Stowasser Frank
• Tuffilli Nicola
• Von Matt Anette
• Wolf Romain
• Zecri Frederic

Classifications

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• A61P33/06

  Antimalarials · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P33/10

  Anthelmintics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title